Due to the 4- and 11-hour half-lives of D + Q, respectively (Graefe et al., 2001; Christopher et al., 2008), treatment was administered over the course of 3 weeks with a 5 days resting period to ensure clearance of the drug to eliminate the possibility of off target drug effects, as opposed to examining the effect of SC elimination on CD4 T cells prior to infection. The gene discussed is CD4; the disease is infection.